

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
103364702US

SERIAL NO. 097787888

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT
Anders PETTERSSON and Christer
NYSTROMFILING DATE
March 26, 2001

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
<i>MP</i>	AG	EP 0 144 243	06/85	Europe	—	—	Yes
<i>MP</i>	AH	EP 0 324 725	07/89	Europe	—	—	Yes
	AI						
	AJ						
	AK						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

<i>MP</i>	AL	Farrar JT et al. "Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients", J Natl Cancer Inst (United States) Apr 15 1998, Vol. 90, No. 8, pp 611-6
	AM	
	AN	

EXAMINER

DATE CONSIDERED

2-15-04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.